The problem w soli is not the SEC trying to ruin it, though it did go to far last year in its ruling.
As far as I can guess w any educated sense, this is an accounting problem related to a designation of shares made in 2020. Perhaps the sale of clinical herbs?
Honestly I don’t know… but you seem to be implicating something here that is not relevant in my eyes.
News 
Market Data 
Discover 
